Are you Dr. Critchfield?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 22 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6170 S Murdoch Woods Pl
Holladay, UT 84121Phone+1 801-541-2322
Summary
- Dr. Gregory Critchfield, MD is a board certified pathologist in Holladay, Utah. He is currently licensed to practice medicine in Utah, Michigan, and Minnesota.
Education & Training
University of MinnesotaResidency, Pathology-Anatomic and Clinical, 1981 - 1985
University of Michigan Health SystemInternship, Transitional Year, 1980 - 1981
University of Utah School of MedicineClass of 1980
Certifications & Licensure
UT State Medical License 1987 - 2026
MI State Medical License 1985 - 1992
MN State Medical License 1981 - 1988- American Board of Pathology Clinical Pathology
Publications & Presentations
PubMed
- Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38].Chad Bradford, Rob Severinsen, Trina Pugmire, Matison Rasmussen, Kathryn Stoddard
Journal of Mass Spectrometry and Advances in the Clinical Lab. 2022-08-01 - 82 citationsDevelopment and validation of a spontaneous preterm delivery predictor in asymptomatic women.George R. Saade, Kim A. Boggess, Scott Sullivan, Glenn Markenson, Jay D. Iams
American Journal of Obstetrics and Gynecology. 2016-05-01 - 42 citationsBody surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX reg...Jennifer Saam, Gregory C. Critchfield, Stephanie A. Hamilton, Benjamin B. Roa, Richard J. Wenstrup
Clinical Colorectal Cancer. 2011-09-01
Press Mentions
Sera Prognostics (NASDAQ: SERA) Releases Positive Data from AVERT PRETERM TrialFebruary 15th, 2023- Sera Prognostics Announces Positive Top-Line Data from AVERT PRETERM TRIALFebruary 15th, 2023
- FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICSNovember 29th, 2022
- Join now to see all
